MiR-122 in hepatic function and liver diseases

Abstract

As the most abundant liver-specific microRNA, microRNA-122 (miR-122) is involved in various physiological processes in hepatic function as well as in liver pathology. There is now compelling evidence that miR-122, as a regulator of gene networks and pathways in hepatocytes, plays a central role in diverse aspects of hepatic function and in the progress of liver diseases. This liver-enriched transcription factors-regulated miRNA promotes differentiation of hepatocytes and regulates lipid metabolism. With regard to liver diseases, miR-122 was shown to stimulate hepatitis C virus (HCV) replication through a unique and unusual interaction with two binding sites in the 5′-UTR of HCV genome to mediate the stability of the viral RNA, whereas inhibit the expression and replication of hepatitis B virus (HBV) by a miR-122-cylin G1/p53-HBV enhancer regulatory pathway. In addition, miR-122 acts as a suppressor of cell proliferation and malignant transformation of hepatocytes with remarkable tumor inhibition activity. Notably, a clinical trial targeting miR-122 with the anti-miR-122 oligonucleotides miravirsen, the first miRNA targeted drug, has been initiated for treatment of HCV infection. With further understanding of the comprehensive roles of miR-122 in hepatic functions and the mechanisms involved in miR-122 down-regulation in chronic hepatitis or hepatocellular carcinoma, miR-122 appears to be a promising candidate for effective therapeutic approaches against tumor and infectious diseases.

Keywords

miR-122 / liver development / lipid metabolism / hepatitis C virus (HCV) / hepatitis B virus (HBV) / hepatocellular carcinoma (HCC)

References

[1] Bai, S., Nasser, M.W., Wang, B., Hsu, S.H., Datta, J., Kutay, H., Yadav, A., Nuovo, G., Kumar, P., and Ghoshal, K. (2009). MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 284, 32015-32027 .10.1074/jbc.M109.016774
[2] Belver, L., de Yébenes, V.G., and Ramiro, A.R. (2010). MicroRNAs prevent the generation of autoreactive antibodies. Immunity 33, 713-722 .10.1016/j.immuni.2010.11.010
[3] Burchard, J., Zhang, C., Liu, A.M., Poon, R.T., Lee, N.P., Wong, K.F., Sham, P.C., Lam, B.Y., Ferguson, M.D., Tokiwa, G., . (2010). microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol 6, 1-12 .10.1038/msb.2010.58
[4] Burns, D.M., D’Ambrogio, A., Nottrott, S., and Richter, J.D. (2011). CPEB and two poly(A) polymerases control miR-122 stability and p53 mRNA translation. Nature 473, 105-108 .10.1038/nature09908
[5] Carissimi, C., Fulci, V., and Macino, G. (2009). MicroRNAs: novel regulators of immunity. Autoimmun Rev 8, 520-524 .10.1016/j.autrev.2009.01.008
[6] Chang, J., Guo, J.T., Jiang, D., Guo, H., Taylor, J.M., and Block, T.M. (2008). Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol 82, 8215-8223 .10.1128/JVI.02575-07
[7] Chen, S., Ni, M., Yu, B., Lv, T., Lu, M., and Gong, F. (2007). Construction and identification of a human liver specific microRNA eukaryotic expression vector. Cell Mol Immunol 4, 473-477 .
[8] Chen, Y., Shen, A., Rider, P.J., Yu, Y., Wu, K., Mu, Y., Hao, Q., Liu, Y., Gong, H., Zhu, Y., . (2011). A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J 25, 4511-4521 .10.1096/fj.11-187781
[9] Coulouarn, C., Factor, V.M., Andersen, J.B., Durkin, M.E., and Thorgeirsson, S.S. (2009) Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28, 3526-3536 .10.1038/onc.2009.211
[10] Díaz-Toledano, R., Ariza-Mateos, A., Birk, A., Martínez-García, B., and Gómez, J. (2009). In vitro characterization of a miR-122-sensitive double-helical switch element in the 5′ region of hepatitis C virus RNA. Nucleic Acids Res 37, 5498-5510 .10.1093/nar/gkp553
[11] Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtj?rn, M., Hansen, H.F., Berger, U., . (2008a). LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899 .10.1038/nature06783
[12] Elmén, J., Lindow, M., Silahtaroglu, A., Bak, M., Christensen, M., Lind-Thomsen, A., Hedtj?rn, M., Hansen, J.B., Hansen, H.F., Straarup, E.M., . (2008b). Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 36, 1153-1162 .10.1093/nar/gkm1113
[13] Esau, C., Davis, S., Murray, S.F., Yu, X.X., Pandey, S.K., Pear, M., Watts, L., Booten, S.L., Graham, M., McKay, R., . (2006). miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3, 87-98 .10.1016/j.cmet.2006.01.005
[14] Esau, C.C. (2008). Inhibition of microRNA with antisense oligonucleotides. Methods 44, 55-60 .10.1016/j.ymeth.2007.11.001
[15] Fan, C.G., Wang, C.M., Tian, C., Wang, Y., Li, L., Sun, W.S., Li, R.F., and Liu, Y.G. (2011). miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. Oncol Rep 26, 1281-1286 .
[16] Filipowicz, W., and Grosshans, H. (2011). The liver-specific microRNA miR-122: biology and therapeutic potential. Prog Drug Res 67, 221-238 .
[17] Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 .10.1038/35888
[18] Fornari, F., Gramantieri, L., Giovannini, C., Veronese, A., Ferracin, M., Sabbioni, S., Calin, G.A., Grazi, G.L., Croce, C.M., Tavolari, S., . (2009). MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 69, 5761-5767 .10.1158/0008-5472.CAN-08-4797
[19] Girard, M., Jacquemin, E., Munnich, A., Lyonnet, S., and Hen-rion-Caude, A. (2008). miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 48, 648-656 .10.1016/j.jhep.2008.01.019
[20] Henke, J.I., Goergen, D., Zheng, J., Song, Y., Schüttler, C.G., Fehr, C., Jünemann, C., and Niepmann, M. (2008). microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 27, 3300-3310 .10.1038/emboj.2008.244
[21] Jangra, R.K., Yi, M., and Lemon, S.M. (2010). Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol 84, 6615-6625 .10.1128/JVI.00417-10
[22] Jopling, C.L., Yi, M., Lancaster, A.M., Lemon, S.M., and Sarnow, P. (2005). Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309, 1577-1581 .10.1126/science.1113329
[23] Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. (2011). Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 27Dec2011. 10.1002/mc.2186410.1002/mc.21864
[24] Kasinski, A.L., and Slack, F.J. (2011). Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 11, 849-864 .10.1038/nrc3166
[25] Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., Manoharan, M., and Stoffel, M. (2005). Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438, 685-689 .10.1038/nature04303
[26] Kummee, P., Tangkijvanich, P., Poovorawan, Y., and Hirankarn, N. (2007). Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat 14, 841-848 .
[27] Lanford, R.E., Hildebrandt-Eriksen, E.S., Petri, A., Persson, R., Lindow, M., Munk, M.E., Kauppinen, S., and ?rum, H. (2010). Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201 .10.1126/science.1178178
[28] Laudadio, I., Manfroid, I., Achouri, Y., Schmidt, D., Wilson, M.D., Cordi, S., Thorrez, L., Knoops, L., Jacquemin, P., Schuit, F., . (2012). A feedback loop between the liver-enriched transcription factor network and miR-122 controls hepatocyte differentiation. Gastroenterology 142, 119-129 .10.1053/j.gastro.2011.09.001
[29] Lewis, B.P., Burge, C.B., and Bartel, D.P. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20 .10.1016/j.cell.2004.12.035
[30] Lindsay, M.A. (2008). microRNAs and the immune response. Trends Immunol 29, 343-351 .10.1016/j.it.2008.04.004
[31] Luo, X., Yang, W., Ye, D.Q., Cui, H., Zhang, Y., Hirankarn, N., Qian, X., Tang, Y., Lau, Y.L., de Vries, N., . (2011). A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet 7, e1002128.10.1371/journal.pgen.1002128
[32] Ma, L., Liu, J., Shen, J., Liu, L., Wu, J., Li, W., Luo, J., Chen, Q., and Qian, C. (2010). Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Therapy 9, 554-561 .10.4161/cbt.9.7.11267
[33] Miyoshi, K., Okada, T.N., Siomi, H., and Siomi, M.C. (2009). Characterization of the miRNA-RISC loading complex and miRNA-RISC formed in the Drosophila miRNA pathway. RNA 15, 1282-1291 .10.1261/rna.1541209
[34] Mizuguchi, Y., Mishima, T., Yokomuro, S., Arima, Y., Kawahigashi, Y., Shigehara, K., Kanda, T., Yoshida, H., Uchida, E., Tajiri, T., . (2011). Sequencing and bioinformatics-based analyses of the microRNA transcriptome in hepatitis B-related hepatocellular carcinoma. PLoS One 6, e15304.10.1371/journal.pone.0015304
[35] Moore, K.J., Rayner, K.J., Suárez, Y., and Fernández-Hernando, C. (2010). microRNAs and cholesterol metabolism. Trends Endocrinol Metab 21, 699-706 .10.1016/j.tem.2010.08.008
[36] Morita, K., Taketomi, A., Shirabe, K., Umeda, K., Kayashima, H., Ninomiya, M., Uchiyama, H., Soejima, Y., and Maehara, Y. (2011). Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int 31, 474-484 .10.1111/j.1478-3231.2010.02433.x
[37] Murchison, E.P., Stein, P., Xuan, Z., Pan, H., Zhang, M.Q., Schultz, R.M., and Hannon, G.J. (2007). Critical roles for Dicer in the female germline. Genes Dev 21, 682-693 .10.1101/gad.1521307
[38] Narbus, C.M., Israelow, B., Sourisseau, M., Michta, M.L., Hopcraft, S.E., Zeiner, G.M., and Evans, M.J. (2011). HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J Virol 85, 12087-12092 .10.1128/JVI.05843-11
[39] Newman, M.A., and Hammond, S.M. (2010). Emerging paradigms of regulated microRNA processing. Genes Dev 24, 1086-1092 .10.1101/gad.1919710
[40] Norman, K.L., and Sarnow, P. (2010). Modulation of hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR-122 involves distinct mechanisms. J Virol 84, 666-670 .10.1128/JVI.01156-09
[41] Pang, P.S., Pham, E.A., Elazar, M., Patel, S.G., Eckart, M.R., and Glenn, J.S. (2012). Structural map of a Pan PS, microRNA-122: Hepatitis C virus complex. J Virol 86, 1250-1254 .10.1128/JVI.06367-11
[42] Pedersen, I.M., Cheng, G., Wieland, S., Volinia, S., Croce, C.M., Chisari, F.V., and David, M. (2007). Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449, 919-922 .10.1038/nature06205
[43] Ramezani, A., Hasanjani Roshan, M.R., Kalantar, E., Eslamifar, A., Banifazl, M., Taeb, J., Aghakhani, A., Gachkar, L., and Velayati, A.A. (2008). Association of human leukocyte antigen polymorphism with outcomes of hepatitis B virus infection. J Gastroenterol Hepatol 23, 1716-1721 .10.1111/j.1440-1746.2008.05482.x
[44] Reinhart, B.J., Slack, F.J., Basson, M., Pasquinelli, A.E., Bettinger, J.C., Rougvie, A.E., Horvitz, H.R., and Ruvkun, G. (2000). The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403, 901-906 .10.1038/35002607
[45] Rusca, N., and Monticelli, S. (2011). MiR-146a in Immunity and Disease. Mol Biol Int 2011, 437301.10.4061/2011/437301
[46] Sage, J., Ventura, A., and Macino, G. (2011). miR than meets the eye. Genes Dev 25, 1663-1667 .10.1101/gad.17454011
[47] Sarasin-Filipowicz, M., Krol, J., Markiewicz, I., Heim, M.H., and Filipowicz, W. (2009). Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 15, 31-33 .10.1038/nm.1902
[48] Shan, Y., Zheng, J., Lambrecht, R.W., and Bonkovsky, H.L. (2007). Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 133, 1166-1174 .10.1053/j.gastro.2007.08.002
[49] Shimakami, T., Yamane, D., Jangra, R.K., Kempf, B.J., Spaniel, C., Barton, D.J., and Lemon, S.M. (2012). Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci U S A 109, 941-946 .10.1073/pnas.1112263109
[50] Starczynowski, D.T., Kuchenbauer, F., Argiropoulos, B., Sung, S., Morin, R., Muranyi, A., Hirst, M., Hogge, D., Marra, M., Wells, R.A., . (2010). Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 16, 49-58 .10.1038/nm.2054
[51] Tan, A.T., Loggi, E., Boni, C., Chia, A., Gehring, A.J., Sastry, K.S., Goh, V., Fisicaro, P., Andreone, P., Brander, C., . (2008). Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol 82, 10986-10997 .10.1128/JVI.01124-08
[52] Wang S, Qiu L, Yan X, Jin W, Wang Y, Chen L, Wu E, Ye X, Gao GF, Wang F, Chen Y, Duan Z, Meng S. (2012). Loss of MiR-122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G1 modulated P53 activity. Hepatology 23Feb2012. 10.1002/hep.2480910.1002/hep.24809
[53] Xu, H., He, J.H., Xiao, Z.D., Zhang, Q.Q., Chen, Y.Q., Zhou, H., and Qu, L.H. (2010). Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 52, 1431-1442 .10.1002/hep.23818
[54] Xu, J., Zhu, X., . (2012). MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/beta-catenin pathway. Liver Int 26Jan2012. 10.1111/j.1478-3231.2011.02750.x10.1111/j.1478-3231.2011.02750.x
[55] Xu, Y., Xia, F., Ma, L., Shan, J., Shen, J., Yang, Z., Liu, J., Cui, Y., Bian, X., Bie, P., . (2011). MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 310, 160-169 .
[56] Yang, F., Zhang, L., Wang, F., Wang, Y., Huo, X.S., Yin, Y.X., Wang, Y.Q., Zhang, L., and Sun, S.H. (2011). Modulation of the unfolded protein response is the core of microRNA-122-involved sensitivity to chemotherapy in hepatocellular carcinoma. Neoplasia 13, 590-600 .
[57] Zeng, C., Wang, R., Li, D., Lin, X.J., Wei, Q.K., Yuan, Y., Wang, Q., Chen, W., and Zhuang, S.M. (2010). A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology 52, 1702-1712 .10.1002/hep.23875
[58] Zhang, L., Zhang, B., Valdez, J.M., Wang, F., Ittmann, M., and Xin, L. (2010). Dicer ablation impairs prostate stem cell activity and causes prostate atrophy. Stem Cells 28, 1260-1269 .
[59] Zhou, X., Jeker, L.T., Fife, B.T., Zhu, S., Anderson, M.S., McManus, M.T., and Bluestone, J.A. (2008). Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med 205, 1983-1991 .10.1084/jem.20080707